Dipeptidyl peptidase IV inhibitors for the treatment of diabetes.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2004-08-12

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/JM030628VPMID 15293982
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes.

  2004cited by this paper
• 4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors.

  2004cited by this paper
• Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition.

  2003cited by this paper
• Inhibition of dipeptidyl peptidase IV (DPP IV) by 2-(2-amino-1-fluoro-propylidene)-cyclopentanecarbonitrile, a fluoroolefin containing peptidomimetic.

  2003cited by this paper
• The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism

  2003cited by this paper
• Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII.

  2003cited by this paper
• Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV.

  2003cited by this paper
• Prolyl peptidases: a serine protease subfamily with high potential for drug discovery.

  2003cited by this paper
• Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.

  2003cited by this paper
• 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.

  2003cited by this paper
• The multifunctional or moonlighting protein CD26/DPPIV.

  2003cited by this paper
• Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

  2003cited by this paper
• Degradation of endomorphin-2 at the supraspinal level in mice is initiated by dipeptidyl peptidase IV: an in vitro and in vivo study.

  2003cited by this paper
• Rapid parallel synthesis of dipeptide diphenyl phosphonate esters as inhibitors of dipeptidyl peptidases.

  2003cited by this paper
• Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog

  2003cited by this paper
• Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteases.

  2003cited by this paper
• High-resolution structure of human apo dipeptidyl peptidase IV/CD26 and its complex with 1-[([2-[(5-iodopyridin-2-yl)amino]-ethyl]amino)-acetyl]-2-cyano-(S)-pyrrolidine.

  2003cited by this paper
• Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies.

  2003cited by this paper
• Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

  2003cited by this paper
• The Role of Dipeptidyl Peptidase IV in the Cleavage of Glucagon Family Peptides

  2003cited by this paper
• Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

  2003cited by this paper
• Gastric inhibitory polypeptide: the neglected incretin revisited.

  2002cited by this paper
• Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats.

  2002cited by this paper
• Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV.

  2002cited by this paper
• 1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(S)-pyrrolidinecarbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.

  2002cited by this paper
• Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes.

  2002cited by this paper
• A Reg family protein is overexpressed in islets from a patient with new-onset type 1 diabetes and acts as T-cell autoantigen in NOD mice.

  2002cited by this paper
• Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice.

  2002cited by this paper
• Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats.

  2002cited by this paper
• Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats.

  2002cited by this paper
• Development of potent and selective dipeptidyl peptidase II inhibitors.

  2002cited by this paper
• Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study.

  2002cited by this paper
• Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats.

  2001cited by this paper
• Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities?

  2001cited by this paper
• Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

  2000cited by this paper
• Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide.

  2000cited by this paper
• New frontiers in the biology of GLP-2.

  2000cited by this paper
• Thioxo amino acid pyrrolidides and thiazolidides: new inhibitors of proline specific peptidases.

  2000cited by this paper
• A guardian angel: the involvement of dipeptidyl peptidase IV in psychoneuroendocrine function, nutrition and immune defence.

  2000cited by this paper
• Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8.

  2000cited by this paper
• 1-Aminomethylisoquinoline-4-carboxylates as novel dipeptidylpeptidase IV inhibitors.

  2000cited by this paper
• Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.

  2000cited by this paper
• Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides.

  1999cited by this paper
• Sequence, Purification, and Cloning of an Intracellular Serine Protease, Quiescent Cell Proline Dipeptidase*

  1999cited by this paper
• Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7–36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

  1999cited by this paper
• NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV.

  1999cited by this paper
• CD26, let it cut or cut it down.

  1999cited by this paper
• Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase IV.

  1999cited by this paper
• The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors.

  1999cited by this paper
• Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.

  1998cited by this paper
• Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide

  1998cited by this paper
• In vivo inhibition of dipeptidyl peptidase IV activity by pro-pro-diphenyl-phosphonate (Prodipine).

  1997cited by this paper
• Proline specific peptidases.

  1997cited by this paper
• Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients.

  1997cited by this paper
• Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV.

  1997cited by this paper
• Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

  1995cited by this paper
• Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

  1995cited by this paper
• Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.

  1993cited by this paper
• Extended investigation of the substrate specificity of dipeptidyl peptidase IV from pig kidney.

  1991cited by this paper
• Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes.

  1991cited by this paper
• Mechanism of proline-specific proteinases: (I) Substrate specificity of dipeptidyl peptidase IV from pig kidney and proline-specific endopeptidase from Flavobacterium meningosepticum.

  1988cited by this paper
• Isolation and characterization of dipeptidyl peptidase IV from human placenta.

  1982cited by this paper
• The incretin concept today

  1979cited by this paper

• Exploring DPP-4: Implications in diverse diseases and structural insights for novel inhibitor design.

  2025cites this paper
• Quantum-Chemical Investigation, Reactivity, NBO, Docking-Based Exploration and in Silico Pharmacological Properties of 3-Bromo-2-[(2Z)-2-(2-oxonaphthalen-1(2H)-ylidene)hydrazinyl]benzoic Acid

  2025cites this paper
• Determination of absolute bioavailability, absorption, metabolism, and excretion of evogliptin in healthy male subjects using a microtracer method.

  2025cites this paper
• Review of plants as a promising source of bioactive peptides for the treatment of diabetes

  2025cites this paper
• GLP-1/GIP Agonist as an Intriguing and Ultimate Remedy for Combating Alzheimer's Disease through its Supporting DPP4 Inhibitors: A Review.

  2024cites this paper
• Exploring Triazole Derivatives as DPP IV Inhibitors: Advancing Type II Diabetes Treatment via Molecular Structure Investigation and Pharmacophore Modelling

  2024cites this paper
• Natural hypoglycaemic bioactives: Newer avenues and newer possibilities

  2024cites this paper
• Therapeutic potential inhibitor for dipeptidyl peptidase IV in diabetic type 2: in silico approaches

  2024cites this paper
• An Update on Dipeptidyl Peptidase-IV Inhibiting Peptides.

  2024cites this paper
• Activatable Fluorescence and Bio/Chemiluminescence Probes for Aminopeptidases: From Design to Biomedical Applications

  2024cites this paper
• A new synthesis of 7H-pyrrolo[3,2-f]quinoxaline derivatives by a one-pot, three-component reaction

  2024cites this paper
• The Potential for Multi-Disease Treatment: Applications of Dipeptidyl Peptidase Inhibitors

  2024cites this paper
• On the origins of SARS-CoV-2 main protease inhibitors.

  2024cites this paper
• Development of Long-Acting Dipeptidyl Peptidase-4 Inhibitors: Structural Evolution and Long-Acting Determinants.

  2023cites this paper
• Brown Seaweed Consumption as a Promising Strategy for Blood Glucose Management: A Comprehensive Meta-Analysis

  2023cites this paper
• A Comprehensive Review on Journey of Pyrrole Scaffold against Multiple Therapeutic Targets.

  2022cites this paper
• Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?

  2022cites this paper
• Review on Analytical Methods for Estimation of Vildagliptin in Bulk and Pharmaceutical Dosage form

  2021cites this paper
• In vitro study of the drug–drug interaction potential of cetagliptin and clinical study of pharmacokinetic interaction of cetagliptin and metformin in healthy volunteers

  2021cites this paper
• Two methods for the preparation of sitagliptin phosphate via chemical resolution and asymmetric hydrogenation

  2021cites this paper
• Quantification Of Novel Dpp4 Inhibitor - Vildagliptin By Spectrophotometric And Chromatographic Techniques: Brief Review

  2021cites this paper
• A double‐blind, randomized, placebo and positive‐controlled study in healthy volunteers to evaluate pharmacokinetic and pharmacodynamic properties of multiple oral doses of cetagliptin

  2021cites this paper
• Asymmetric organocatalysis: an enabling technology for medicinal chemistry.

  2021cites this paper
• Pyrrolotriazinone as an Underexplored Scaffold in Drug Discovery

  2021cites this paper
• Highly Enantioselective Synthesis of Sitagliptin

  2020cites this paper
• In silico screening of potential antidiabetic phytochemicals from Phyllanthus emblica against therapeutic targets of type 2 diabetes.

  2020cites this paper
• Dipeptidyl‐peptidases: Key enzymes producing entry forms of extracellular proteins in asaccharolytic periodontopathic bacterium Porphyromonas gingivalis

  2020cites this paper
• Stereo- and Enantioselective Addition of Organolithiums to 2-Oxazolinylazetidines as a Synthetic Route to 2-Acylazetidines

  2019cites this paper
• Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes

  2019cites this paper
• Prevention and treatment effects of edible berries for three deadly diseases: Cardiovascular disease, cancer and diabetes

  2019cites this paper
• Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibase®

  2019cites this paper
• The Chiral Bioconversion and Pharmacokinetic Analysis of Trelagliptin in Beagle Dog Plasma by LC-MS/MS.

  2019cites this paper
• Natural phenolic compounds potentiate hypoglycemia via inhibition of Dipeptidyl peptidase IV

  2019cites this paper
• Establishment of potent and specific synthetic substrate for dipeptidyl-peptidase 7.

  2018cites this paper
• Critical Role of Dipeptidyl Peptidase IV: A Therapeutic Target for Diabetes and Cancer.

  2018cites this paper
• Chromatographic separation of vildagliptin and l‐proline as in‐process impurity with the application of Youden's test and statistical analysis to test the robustness of the HPLC method

  2018cites this paper
• Current anti-diabetic agents and their molecular targets: A review.

  2018cites this paper
• Food-Derived Bioactive Peptides as Functional Ingredients for the Management of Type-2 Diabetes

  2018cites this paper
• Pyrrole: An insight into recent pharmacological advances with structure activity relationship.

  2018cites this paper
• A manganese-salen complex as dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

  2018cites this paper
• Activity and selectivity cliffs for DPP‐IV inhibitors: Lessons we can learn from SAR studies and their application to virtual screening

  2018cites this paper
• PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DABETES

  2017cites this paper
• Synthesis and characterization of oxidovanadium complexes as enzyme inhibitors targeting dipeptidyl peptidase IV.

  2017cites this paper
• Recent advances in synthetic facets of immensely reactive azetidines

  2017cites this paper
• Improved Synthesis of (R)‐3‐(t‐Butoxycarbonylamino)‐4‐(2,4,5‐trifluorophenyl)butanoic Acid as a Key Intermediate for the Synthesis of Sitagliptin

  2017cites this paper
• Concise synthesis of valuable chiral N-Boc-β-benzyl-β-amino acid via construction of chiral N-Boc-3-benzyl-5-oxoisoxazolidine through cross-metathesis/conjugate addition/oxidation

  2017cites this paper
• Degradation of Incretins and Modulation of Blood Glucose Levels by Periodontopathic Bacterial Dipeptidyl Peptidase 4

  2017cites this paper
• Insilco molecular docking study of Dihydroisoquinolinium Derivatives as DPP IV Inhibitors in Type II Diabetes Mellitus

  2017cites this paper
• STABILITY INDICATING RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS DETERMINATION OF VILDAGLIPTIN AND METFORMIN IN PHARMACEUTICAL DOSAGE FORM

  2017cites this paper
• SVMDLF: A novel R‐based Web application for prediction of dipeptidyl peptidase 4 inhibitors

  2017cites this paper
• Thioamide Substitution Selectively Modulates Proteolysis and Receptor Activity of Therapeutic Peptide Hormones.

  2017cites this paper
• Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes.

  2016cites this paper
• Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.

  2016cites this paper
• In-silico Structure Modeling and Docking Studies Using Dipeptidyl Peptidase 4 (DPP4) Inhibitors against Diabetes Type-2

  2016cites this paper
• Direct Synthesis of Cyanopyrrolidinyl β‐Amino Alcohols for the Development of Diabetes Therapeutics

  2016cites this paper
• Stereoselective Synthesis of Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitor, (R)‐Sitagliptin

  2016cites this paper
• Diabetes and Health Care: An Overview

  2016cites this paper
• Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice

  2016cites this paper
• Glycogen phosphorylase inhibitors: a patent review (2013 - 2015)

  2016cites this paper
• A decade update on solvent and catalyst-free neat organic reactions: a step forward towards sustainability

  2016cites this paper
• Discovery of gastric inhibitory polypeptide and its subsequent fate: Personal reflections

  2016cites this paper
• Determination of the Enantiomeric Purity of Trelagliptin by Pre-Column Derivatization and Liquid Chromatography on a Chiral Stationary Phase

  2015cites this paper
• Evaluation of some plants for potential dipeptidyl peptidase IV inhibitory effects in vitro

  2015cites this paper
• Structure-activity-relationship of amide and sulfonamide analogs of omarigliptin.

  2015cites this paper
• An overview of recent dipeptidyl peptidase-IV inhibitors: linking their structure and physico-chemical properties with sar, pharmacokinetics and toxicity.

  2015cites this paper
• EFFECT OF CINNAMOMUM CASSIA BARK EXTRACT ON GLUCOSE HOMEOSTASIS IN ALLOXAN-INDUCED DIABETIC RATS IN COMPARISON WITH DIRECT RENIN INHIBITOR (ALISKIREN) AND DIPEPTIDYL PEPTIDASE-IV INHIBITOR (SITAGLIPTIN)

  2015cites this paper
• Food protein-derived bioactive peptides in management of type 2 diabetes

  2015cites this paper
• Design, synthesis and biological evaluation of hetero-aromatic moieties substituted pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors.

  2014cites this paper
• A SIMPLE AND VALIDATED RP-HPLC METHOD FOR THE SIMULTANEOUS DETERMINATION OF VILDAGLIPTIN AND METFORMIN IN BULK AND PHARMACEUTICAL DOSAGE FORMS

  2014cites this paper
• Mitigation of Endothelial Dysfunction by Saxagliptin in High-Fat Diet/Streptozotocin-Induced Diabetic Rats

  2014cites this paper
• Novel hydrazine derivatives as selective DPP-IV inhibitors: findings from virtual screening and validation through molecular dynamics simulations

  2014cites this paper
• Identification of Dipeptidyl Peptidase IV Inhibitors: Virtual Screening, Synthesis and Biological Evaluation

  2014cites this paper
• MK-0626, a dipeptidyl peptidase-4 inhibitor, improves neovascularization by increasing both the number of circulating endothelial progenitor cells and endothelial nitric oxide synthetase expression.

  2014cites this paper
• Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors.

  2014cites this paper
• Development of Large-Scale Synthesis using a Palladium-Catalyzed Cross-Coupling Reaction for an Isoquinolone Derivative as a Potent DPP-4 Inhibitor

  2014cites this paper
• Novel DPP-4 inhibitors against diabetes.

  2014cites this paper
• Sixteen-years of clinically relevant dipeptidyl peptidase-IV (DPP-IV) inhibitors for treatment of type-2 diabetes: a perspective.

  2014cites this paper
• Chameleonic reactivity of α-amino nitrile-derived ureas. Synthesis of highly functionalized imidazolidin-2-one and imidazolidine-2,4-dione derivatives

  2014cites this paper
• Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?

  2014cites this paper
• Design, synthesis and biological evaluation of 4-fluoropyrrolidine-2-carbonitrile and octahydrocyclopenta[b]pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors.

  2014cites this paper
• Validated LC-MS/MS method for simultaneous determination of Dasatinib and Sitagliptin in rat plasma and its application to pharmacokinetic study

  2014cites this paper
• Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.

  2014cites this paper
• Structure based virtual screening of MDPI database: discovery of structurally diverse and novel DPP-IV inhibitors.

  2014cites this paper
• Uric acid inhibition of dipeptidyl peptidase IV in vitro is dependent on the intracellular formation of triuret.

  2014cites this paper
• MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice.

  2014cites this paper
• DPP 4 INHIBITORS: A NEW ERA OF TREATING TYPE 2 DIABETES MELLITUS

  2014cites this paper
• Development and Validation of Simultaneously Estimation of Vildagliptin & Metformin Hydrochloride by RP-HPLC in Bulk and Oral Dosage Form

  2014cites this paper
• DPP-IV, An Important Target for Antidiabetic Functional Food Design

  2014cites this paper
• Synthesis, invitro and invivo anti-hyperglycemic activity of1,2,4-triazolebenzylidene and 1,3,4-thiadiazole derivatives

  2014cites this paper
• Efficient stereocontrolled synthesis of sitagliptin phosphate

  2014cites this paper
• DEVELOPMENT AND VALIDATION OF HPLC METHOD FOR THE ESTIMATION OF VILDAGLIPTIN IN PHARMACEUTICAL DOSAGE FORM

  2014cites this paper
• SAFETY AND EFFICACY OF SITAGLIPTIN COMPARED WITH GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED WITH METFORMIN MONOTHERAPY

  2013cites this paper
• Berry and Citrus Phenolic Compounds Inhibit Dipeptidyl Peptidase IV: Implications in Diabetes Management

  2013cites this paper
• New leads for DPP IV inhibition: structure-based pharmacophore mapping and virtual screening study

  2013cites this paper
• Alogliptin and its benzoate salt.

  2013cites this paper
• Solvent-free synthesis of α-amino nitrile-derived ureas.

  2013cites this paper
• Pharmacokinetic–Pharmacodynamic Modelling of Biomarker Response to Sitagliptin in Healthy Volunteers

  2013cites this paper
• RP-HPLC determination of vildagliptin in pure and in tablet formulation

  2013cites this paper
• DP IV/CD26 Effector Peptides

  2013cites this paper
• Predicting the DPP-IV Inhibitory Activity pIC50 Based on Their Physicochemical Properties

  2013cites this paper